Compare NBY & HPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NBY | HPI |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Trusts Except Educational Religious and Charitable |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 433.9M |
| IPO Year | 2007 | 2002 |
| Metric | NBY | HPI |
|---|---|---|
| Price | $1.48 | $16.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 954.5K | 62.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $370,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.05 | N/A |
| P/E Ratio | $1.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $14.61 |
| 52 Week High | $19.95 | $17.61 |
| Indicator | NBY | HPI |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 42.35 |
| Support Level | $0.99 | $15.71 |
| Resistance Level | $2.52 | $16.28 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 50.68 | 21.28 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
John Hancock Preferred Income Fund is a closed-end, diversified management investment company. Its primary investment objective is to provide a high-level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve its investment objectives by investing in securities that may be undervalued relative to similar securities in the marketplace. The fund's principal investment strategies include investing a majority of its assets in preferred stocks and other preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, and short-term investments.